Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy

Cancer Investigation

Volumn 15, Issue 4, 1997, Pages 297-303

  Beck, Thomas M ^a   York, Martin ^b   Chang, Alex ^c   Navari, Rudolph ^d   Harvey, Walter H ^e   Meshad, Michael ^e   Griffin, Daniel ^f   Wentz, Alison ^f  

^a St Luke's Mountain States Tumor Institute   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d Simon Williamson Clinic   (United States)

^e Hematol/Oncol Assoc of SW Florida ^*

^f GLAXOSMITHKLINE   (United States)

Author keywords

Chemotherapy; Cyclophosphamide; Nausea; Vomiting

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; ONDANSETRON;

ADULT; AGED; APPETITE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC CANCER; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN CANCER; UROGENITAL TRACT CANCER; VOMITING;

EID: 0030847832     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709039729     Document Type: Article

References (13)

1. Lindley CM, Bernard S, Fields SM: Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 7:1142-1149, 1989.
2. Sagar SM: The current role of anti-emetic drugs in oncology: A recent revolution in patient symptom control. Cancer Treat Rev 18:95-135, 1991.
3. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MHN: On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203-208, 1983.
4. O'Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, Laberge F: Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: Survey of five Canadian centres. Can Med Assoc J 149:296-302, 1993.
5. Lindley CM, Hirsch JD: Nausea and vomiting and cancer patients' quality of life: A discussion of Professor Selby's paper. Br J Cancer 66(Suppl XIX):S26-S29, 1992.
6. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL: Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322:810-816, 1990.
7. Hainsworth J, Harvey W, Pendergrass K, et al: A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9:721-728, 1991.
8. Beck TM, Hesketh PJ, Madajewicz S, et al: Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:1969-1975, 1992.
9. Cubeddu LX, Hoffman IS, Fuenmayor NT, Finn AL: Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J Clin Oncol 8:1721-1727, 1990.
10. Beck TM, Ciociola AA, Jones SE, et al: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 118:407-413, 1993.
11. Beck TM: Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: Review of clinical trials. Semin Oncol 19(Suppl 15):20-25, 1992.
12. Morran C, Smith DC, Anderson DA, et al: Incidence of nausea and vomiting with cytotoxic chemotherapy in a prospective randomised trial of anti-emetics. Br Med J 278:1323-1324, 1979.
13. Kovac AL: Use of serotonin receptor antagonists in the prevention and treatment of nausea and vomiting. Hosp Form 28:988-998, 1993.